Uroporphyria and hepatic carcinogenesis induced by polychlorinated biphenyls-iron interaction: Absence in the Cyp1a2(-/-) knockout mouse

Biochemical and Biophysical Research Communications

Volumn 331, Issue 1, 2005, Pages 147-152

  Greaves, Peter ^a   Clothier, Bruce ^a   Davies, Reginald ^a   Higginson, Fiona M ^a   Edwards, Richard E ^a   Dalton, Timothy P ^b   Nebert, Daniel W ^b   Smith, Andrew G ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Carcinogenesis; Cyp1a2( ) mice; Iron; PCBs; Porphyria

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2B; CYTOCHROME P450 2B10; IRON DEXTRAN; POLYCHLORINATED BIPHENYL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; KNOCKOUT MOUSE; LIVER CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PORPHYRIA; PORPHYRINURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 17444411866     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.03.136     Document Type: Article

References (40)

1. K. Steenland, P. Bertazzi, A. Baccarelli, and M. Kogevinas Dioxin revisited: developments since the 1997 IARC classification of dioxin as a human carcinogen Environ. Health Perspect. 112 2004 1265 1268
2. R. Golden, J. Doull, W. Waddell, and J. Mandel Potential human cancer risks from exposure to PCBs: a tale of two evaluations Crit. Rev. Toxicol. 33 2003 543 580
3. J. Whysner, F. Montandon, R.M. McClain, J. Downing, L.K. Verna, R.E. Steward 3rd, and G.M. Williams Absence of DNA adduct formation by phenobarbital, polychlorinated biphenyls, and chlordane in mouse liver using the 32P-postlabeling assay Toxicol. Appl. Pharmacol. 148 1998 14 23
4. G. Ludewig Cancer initiation by PCBs, in PCBs L.W. Robertson L.G. Hansen Recent advances in environmental toxicology and health effects 2001 University Press of Kentucky Lexington, Kentucky 337 371
5. R. Davies, B. Clothier, and A.G. Smith Mutation frequency in the lacI gene of liver DNA from lambda/lacI transgenic mice following the interaction of PCBs with iron causing hepatic cancer and porphyria Mutagenesis 15 2000 379 383
6. H.P. Glauert, L.W. Robertson, and E.M. Silberhorn PCBs and tumor promotion, in PCBs L.W. Robertson L.G. Hansen Recent advances in environmental toxicology and health effects 2001 University Press of Kentucky Lexington, Kentucky 337 371
7. A.G. Smith Porphyria caused by chlorinated AH receptor ligands and associated mechanisms of liver injury and cancer K.M. Kadish K.M. Smith R. Guilard The porphyrin handbook 2003 Elsevier Amsterdam 169 210
8. A. Smith, J.R.P. Cabral, P. Carthew, J.E. Francis, and M.M. Manson Carcinogenicity of iron in conjunction with a chlorinated environmental chemical, hexachlorobenzene, in C57BL/10ScSn mice Int. J. Cancer 43 1989 492 496
9. A.G. Smith, J.E. Francis, and P. Carthew Iron as a synergist for hepatocellular carcinoma induced by polychlorinated biphenyls in Ah-responsive C57BL/10ScSn mice Carcinogenesis 11 1990 437 444
10. L. Libbrecht, L. Meerman, F. Kuipers, T. Roskams, V. Desmet, and P. Jansen Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria J. Pathol. 199 2003 191 200
11. J.M. Jacobs, P.R. Sinclair, W.J. Bement, R.W. Lambrecht, J.F. Sinclair, and J.A. Goldstein Oxidation of uroporphyrinogen by methylcholanthrene-induced cytochrome P-450. Essential role of cytochrome P-450d Biochem. J. 258 1989 247 253
12. H.C.L. Liang, H. Li, R.A. McKinnon, J.J. Duffy, S.S. Potter, A. Puga, and D.W. Nebert Cyp1a2 (-/-) null mutant mice develop normally but show deficient drug metabolism Proc. Natl. Acad. Sci. USA 93 1996 1671 1676
13. A.G. Smith, R. Davies, T.P. Dalton, M.L. Miller, D. Judah, J. Riley, T. Gant, and D.W. Nebert Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse EHP Toxicogenomics 111 2003 855 861
14. H.G. Shertzer, T.P. Dalton, G. Talaska, and D.W. Nebert Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice Toxicol. Appl. Pharmacol. 181 2002 32 37
15. Y. Tsuneoka, T.P. Dalton, M.L. Miller, C.D. Clay, H.G. Shertzer, G. Talaska, M. Medvedovic, and D.W. Nebert 4-Aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice J. Natl. Cancer Inst. 95 2003 1227 1237
16. P.R. Sinclair, N. Gorman, T. Dalton, H.S. Walton, W.J. Bement, J.F. Sinclair, A.G. Smith, and D.W. Nebert Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice Biochem. J. 330 1998 149 153
17. P.R. Sinclair, N. Gorman, H.S. Walton, W.J. Bement, T.P. Dalton, J.F. Sinclair, A.G. Smith, and D.W. Nebert CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron Toxicol. Appl. Pharmacol. 162 2000 60 67
18. A.G. Smith, B. Clothier, P. Carthew, N.L. Childs, P.R. Sinclair, D.W. Nebert, and T.P. Dalton Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8- tetrachlorodibenzo-p-dioxin Toxicol. Appl. Pharmacol. 173 2001 89 98
19. P.R. Sinclair, W.J. Bement, R.W. Lambrecht, N. Gorman, and J.F. Sinclair Chlorinated biphenyls induce cytochrome P450IA2 and uroporphyrin accumulation in cultures of mouse hepatocytes Arch. Biochem. Biophys. 281 1990 225 232
20. B. Grandchamp, J.C. Deybach, M. Grelier, H. de Verneuil, and Y. Nordmann Studies of porphyrin synthesis in fibroblasts of patients with congenital erythropoietic porphyria and one patient with homozygous coproporphyria Biochim. Biophys. Acta 629 1980 577 586
21. E. Farber, and D.S. Sarma Hepatocarcinogenesis: a dynamic cellular perspective Lab. Invest. 56 1987 4 22
22. M.R. Franklin, J.D. Phillips, and J.P. Kushner Cytochrome P450 induction, uroporphyrinogen decarboxylase depression, porphyrin accumulation and excretion, and gender influence in a 3-week rat model of porphyria cutanea tarda Toxicol. Appl. Pharmacol. 147 1997 289 299
23. J.F. Brown, K.M. Fish, B.A. Mayes, J.B. Silkworth, S.B. Hamilton, and J. Whysner PCB effects on epigenetic carcinogenic processes, in PCBs L.W. Robertson L.G. Hansen Recent advances in environmental toxicology and health effects 2001 University Press of Kentucky Lexington, Kentucky 329 336
24. A.G. Smith, J.E. Francis, J.A. Green, J.B. Greig, C.R. Wolf, and M.M. Manson Sex-linked hepatic uroporphyria and the induction of cytochromes P450IA in rats caused by hexachlorobenzene and polyhalogenated biphenyls Biochem. Pharmacol. 40 1990 2059 2068
25. J. Whysner, and C.X. Wang Hepatocellular iron accumulation and increased cell proliferation in polychlorinated biphenyl-exposed Sprague-Dawley rats and the development of hepatocarcinogenesis Toxicol. Sci. 62 2001 36 45
26. A.G. Smith, P. Carthew, J.E. Francis, J.R. Cabral, and M.M. Manson Enhancement by iron of hepatic neoplasia in rats caused by hexachlorobenzene Carcinogenesis 14 1993 1381 1387
27. A.G. Roberts, S.D. Whatley, R.R. Morgan, M. Worwood, and G.H. Elder Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda Lancet 349 1997 321 323
28. Z.J. Bulaj, J.D. Phillips, R.S. Ajioka, M.R. Franklin, L.M. Griffen, D.J. Guinee, C.Q. Edwards, and J.P. Kushner Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda Blood 95 2000 1565 1571
29. H. Salata, J.M. Cortes, R. Enriquez de Salamanca, H. Oliva, A. Castro, E. Kusak, V. Carreno, and C. Hernandez Guio Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors J. Hepatol. 1 1985 477 487
30. M. Linet, G. Gridley, O. Nyren, L. Mellemkjaer, J. Olsen, S. Keehn, H. Adami, and J. Fraumeni Jr. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden Am. J. Epidemiol. 149 1999 1010 1015
31. A.L. Fracanzani, E. Taioli, M. Sampietro, E. Fatta, C. Bertelli, G. Fiorelli, and S. Fargion Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease J. Hepatol. 35 2001 498 503
32. D.L. Eaton, E.P. Gallagher, T.K. Bammler, and K.L. Kunze Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity Pharmacogenetics 5 1995 259 274
33. D.W. Nebert, R.A. McKinnon, and A. Puga Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer DNA Cell Biol. 15 1996 273 280
34. Z. Jiang, T.P. Dalton, L. Jin, B. Wang, Y. Tsuneoka, H.G. Shertzer, R. Deka, and D.W. Nebert Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2locus Hum. Mutat. 25 2005 196 206
35. D.W. Nebert, T.P. Dalton, A.B. Okey, and F.J. Gonzalez Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer J. Biol. Chem. 279 2004 23847 23850
36. N. Gorman, K.L. Ross, H.S. Walton, W.J. Bement, J.G. Szakacs, G.S. Gerhard, T.P. Dalton, D.W. Nebert, R.S. Eisenstein, J.F. Sinclair, and P.R. Sinclair Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron Hepatology 35 2002 912 921
37. P.C. Burcham Internal hazards: baseline DNA damage by endogenous products of normal metabolism Mutat. Res. 443 1999 11 36
38. S. Knasmuller, W. Parzefall, C. Helma, F. Kassie, S. Ecker, and R. Schulte-Hermann Toxic effects of griseofulvin: disease models, mechanisms, and risk assessment Crit. Rev. Toxicol. 27 1997 495 537
39. T.W. Gant, P.R. Baus, B. Clothier, J. Riley, R. Davies, D.J. Judah, R.E. Edwards, E. George, P. Greaves, and A.G. Smith Gene expression profiles associated with inflammation, fibrosis, and cholestasis in mouse liver after griseofulvin Environ. Health Perspect. 111 2003 847 853
40. R. Davies, A. Schuurman, C.R. Barker, B. Clothier, T. Chernova, F.M. Higginson, D.J. Judah, D. Dinsdale, R.E. Edwards, P. Greaves, T.W. Gant, and A.G. Smith Hepatic gene expression in protoporphyric Fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool Am. J. Pathol. 166 2005 1041 1053